Sphingolipids and cardiovascular diseases: Lipoprotein metabolism, atherosclerosis and cardiomyopathy

Advances in Experimental Medicine and Biology

Volumn 721, Issue , 2011, Pages 19-39

  Jiang, Xian Cheng ^a   Goldberg, Ira J ^b   Park, Tae Sik ^c  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Howard Hughes Medical Institute   (United States)

^c Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CERAMIDE; CHOLESTEROL ESTER; CHYLOMICRON; ENZYME INHIBITOR; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LIPOXAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SERINE PALMITOYLTRANSFERASE; SPHINGOFUNGIN DERIVATIVE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN SYNTHASE 1; SPHINGOMYELIN SYNTHASE 2; SYNTHETASE; THERMOZYMOCIDIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DIABETIC CARDIOMYOPATHY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; INSULIN SENSITIVITY; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; LIPOPROTEIN METABOLISM; LIPOTOXICITY; MACROPHAGE FUNCTION; METABOLIC REGULATION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; CHOLESTEROL; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; FATTY ACIDS; FATTY ACIDS, MONOUNSATURATED; HUMANS; INFLAMMATION; LIPOPROTEINS; MAP KINASE SIGNALING SYSTEM; MODELS, CARDIOVASCULAR; SERINE C-PALMITOYLTRANSFERASE; SPHINGOLIPIDS; TRANSFERASES (OTHER SUBSTITUTED PHOSPHATE GROUPS);

EID: 80053604705     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0650-1_2     Document Type: Article

References (165)

1. Shimabukuro M, Zhou YT, Levi M et al. Fatty acidinduced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998; 95:2498-2502. (Pubitemid 28145970)
2. Koyama K, Chen G, Lee Y et al. Tissue triglycerides, insulin resistance and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol 1997; 273:E708-713.
3. Zhou YT, Grayburn P, Karim A et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97:1784-1789. (Pubitemid 30118520)
4. Dyntar D, Eppenberger-Eberhardt M, Maedler K et al. Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 2001; 50:2105-2113. (Pubitemid 33643679)
5. Petersen KF, ShulmanGI. Etiologyofinsulinresistance. Am JMed 2006; 119:S10-16.
6. Jiang XC, Paultre F, Pearson TAet al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20:2614-2618.
7. Park TS, Panek RL, Mueller SB et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004; 110:3465-3471. (Pubitemid 39602225)
8. Hojjati MR, Li Z, Zhou H et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005; 280:10284-10289. (Pubitemid 40395884)
9. Liu J, Huan C, Chakraborty M et al. Macrophage sphingomyelin synthase 2 (SMS2) deficiency decreases atherosclerosis in mice. Circulation Research. 2009.
10. Park TS, Hu Y, Noh HL et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008; 49:2101-2112.
11. Holland WL, Brozinick JT, Wang LP et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat- and obesityinduced insulin resistance. Cell Metab 2007; 5:167-179.
12. Merrill AH Jr, Jones DD. An update of the enzymology and regulation of sphingomyelin metabolism. Biochim Biophys Acta 1990; 1044:1-12. (Pubitemid 20144101)
13. Weiss B, Stoffel W. Human and murine serine-palmitoyl-CoA transferase-cloning, expression and characterization of the key enzyme in sphingolipid synthesis. Eur J Biochem 1997; 249:239-247. (Pubitemid 27432617)
14. Hanada K, Hara T, Nishijima M et al. A mammalian homolog of the yeast LCB1 encodes a component of serine palmitoyltransferase, the enzyme catalyzing the first step in sphingolipid synthesis. J Biol Chem 1997; 272:32108-32114. (Pubitemid 28011882)
15. Yasuda S, Nishijima M, Hanada K. Localization, topology and function of the LCB1 subunit of serine palmitoyltransferase in mammalian cells. J Biol Chem 2003; 278:4176-4183. (Pubitemid 36801155)
16. Hornemann T, Richard S, Rutti MF et al. Cloning and initial characterization of anew subunit for mammalian serine-palmitoyltransferase. J Biol Chem 2006; 281:37275-37281. (Pubitemid 46042031)
17. Gable K, Slife H, BacikovaD et al. Tsc3p is an 80-amino acid protein associated with serine palmitoyltransferase and required for optimal enzyme activity. J Biol Chem 2000; 275:7597-7603. (Pubitemid 30159659)
18. Han G, Gupta SD, Gable K et al. Identification of small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA substrate specificities. Proc Natl Acad Sci USA 2009; 106:8186-8191.
19. Lipsky NG, Pagano RE. Intracellular translocation of fluorescent sphingolipids in cultured fibroblasts: endogenously synthesized sphingomyelin and glucocerebroside analogues pass through the Golgi apparatus en route to the plasma membrane. J Cell Biol 1985; 100:27-34. (Pubitemid 15151878)
20. Kobayashi T, Pagano RE. Lipid transport during mitosis. Alternative pathways for delivery of newly synthesized lipids to the cell surface. J Biol Chem 1989; 264:5966-5973. (Pubitemid 19098069)
21. Futerman AH, Stieger B, Hubbard AL et al. Sphingomyelin synthesis in rat liver occurs predominantly at the cis and medial cisternae of the Golgi apparatus. J Biol Chem 1990; 265:8650-8657.
22. Marggraf WD, Zertani R, Anderer FA et al. The role of endogenous phosphatidylcholine and ceramide in the biosynthesis of sphingomyelin in mouse fibroblasts. Biochim Biophys Acta 1982; 710:314-323. (Pubitemid 12113271)
23. Malgat M, Maurice A, Baraud J. Sphingomyelin and ceramidephosphoethanolamine synthesis by microsomes and plasma membranes from rat liver and brain. J Lipid Res 1986; 27:251-260. (Pubitemid 16097323)
24. van Helvoort A, van't Hof W, Ritsema T et al. Conversion of diacylglycerol to phosphatidylcholine on the basolateral surface of epithelial (Madin-Darby canine kidney) cells. Evidence for the reverse action of a sphingomyelin synthase. J Biol Chem 1994; 269:1763-1769.
25. Allan D, Obradors MJ. Enzyme distributions in subcellular fractions of BHK cells infected with Semliki forest virus: evidence for a major fraction of sphingomyelin synthase in the trans-golgi network. Biochim Biophys Acta 1999; 1450:277-287. (Pubitemid 29295478)
26. Albi E, Magni MV. Sphingomyelin synthase in rat liver nuclear membrane and chromatin. FEBS Lett 1999; 460:369-372. (Pubitemid 29495971)
27. Albi E, MM. Chromatin-associated sphingomyelin: metabolism in relation to cell function. Cell Biochem Funct 2003; 21:211-215. (Pubitemid 36988373)
28. Huitema K, van den Dikkenberg J, Brouwers JF et al. Identification of a family of animal sphingomyelin synthases. Embo J 2004; 23:33-44. (Pubitemid 38165745)
29. Yamaoka S, Miyaji M, Kitano T et al. Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-defective lymphoid cells. J Biol Chem 2004; 279:18688-18693. (Pubitemid 38623292)
30. Yeang C, Varshney S, Wang R et al. The domain responsible for sphingomyelin synthase (SMS) activity. Biochim Biophys Acta 2008; 1781:610-617.
31. Li Z, Hailemariam TK, Zhou H et al. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization. Biochim Biophys Acta 2007; 1771:1186-1194. (Pubitemid 47404966)
32. Miyaji M, Jin ZX, Yamaoka S et al. Role of membrane sphingomyelin and ceramide in platform formation for Fasmediated apoptosis. J Exp Med 2005; 202:249-259. (Pubitemid 41043821)
33. Van der Luit AH, Budde M, Zerp S et al. Resistance to alkyl-lysophospholipid induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. Biochem J 2007; 401:541-549. (Pubitemid 46166435)
34. Merkel M, Eckel RH Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake and regulation. J Lipid Res 2002; 43:1997-2006. (Pubitemid 35471065)
35. Otarod JK, Goldberg IJ. Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr Atheroscler Rep 2004; 6:335-342. (Pubitemid 39359474)
36. Kuksis A, Breckenridge WC, Myher JJ et al. Replacement of endogenous phospholipids in rat plasma lipoproteins during intravenous infusion of an artificial lipid emulsion. Can J Biochem 1978; 56:630-639. (Pubitemid 8386016)
37. Saito H, Arimoto I, Tanaka M et al. Inhibition of lipoprotein lipase activity by sphingomyelin: role of membrane surface structure. Biochim Biophys Acta 2000; 1486:312-320. (Pubitemid 30618871)
38. Arimoto I, Saito H, Kawashima Y et al. Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J Lipid Res 1998; 39:143-151. (Pubitemid 28063550)
39. Lobo LI, Wilton DC. Combined effects of sphingomyelin and cholesterol on the hydrolysis of emulsion particle triolein by lipoprotein lipase. Biochim Biophys Acta 1997; 1349:122-130. (Pubitemid 27519554)
40. Cantin B, Brun LD, Gagne C et al. Alterations in erythrocyte membrane lipid composition and fluidity in primary lipoprotein lipase deficiency. Biochim Biophys Acta 1992; 1139:25-31.
41. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999; 40:1-16. (Pubitemid 29022581)
42. Kothapalli D, Fuki I, Ali K et al. Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. J Clin Invest 2004; 113:609-618. (Pubitemid 38542510)
43. Huang Y, JiZS, BrechtWJet al. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis. Arterioscler Thromb Vasc Biol 1999; 19:2952-2959. (Pubitemid 30029824)
44. Mensenkamp AR, Jong MC, van Goor H et al. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem 1999; 274:35711-35718. (Pubitemid 129512872)
45. Mahley RW, Huang Y, Weisgraber KH. Putting cholesterol in its place: apoE and reverse cholesterol transport. J Clin Invest 2006; 116:1226-1229.
46. Arimoto I, Matsumoto C, Tanaka M et al. Surface composition regulates clearance from plasma and triolein lipolysis oflipid emulsions. Lipids 1998; 33:773-779. (Pubitemid 28388057)
47. Morita SY, Nakano M, Sakurai A et al. Formation of ceramide-enriched domains in lipid particles enhances the binding ofapolipoprotein E. FEBS Lett 2005; 579:1759-1764. (Pubitemid 40341554)
48. Morita SY, Okuhira K, Tsuchimoto N et al. Effects of sphingomyelin on apolipoprotein E- and lipoprotein lipase-mediated cell uptake oflipid particles. Biochim Biophys Acta 2003; 1631:169-176. (Pubitemid 36287513)
49. Lucie D, Huang ZH, Gu de S et al. Regulation of macrophage apoE secretion and sterol efflux by the LDL receptor. J Lipid Res 2007; 48:366-372. (Pubitemid 46220603)
50. Schlitt A, Hojjati MR, von Gizycki H et al. Serum sphingomyelin levels are related to the clearance of postprandial remnant-like particles. J Lipid Res 2005; 46:196-200. (Pubitemid 40271082)
51. Jeong T, Schissel SL, Tabas I et al. Increased sphingomyelin content ofplasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 1998; 101:905-912. (Pubitemid 28096088)
52. Krieger M. Chartingthe fate ofthe "good cholesterol": identification and characterization ofthe high-density lipoprotein receptor SR-BI. Annu Rev Biochem 1999; 68:523-558. (Pubitemid 29449202)
53. Van Eck M, Pennings M, Hoekstra M et al. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2005; 16:307-315. (Pubitemid 40839760)
54. Barter PJ, Brewer HB Jr, Chapman MJ et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:160-167. (Pubitemid 36231923)
55. Subbaiah PV, Liu M. Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition oflecithincholesterol acyltransferase reaction. J Biol Chem 1993; 268:20156-20163. (Pubitemid 23278915)
56. BolinDJ, Jonas A. Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction withreconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem 1996; 271:19152-19158. (Pubitemid 26271578)
57. Rye KA, Hime NJ, Barter PJ. The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins. J Biol Chem 1996; 271:4243-4250.
58. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect ofhigh density lipoproteins. J Intern Med 2008; 263:256-273. (Pubitemid 351207349)
59. Subbaiah PV, Gesquiere LR, Wang K. Regulation of the selective uptake of cholesteryl esters from high density lipoproteins by sphingomyelin. J Lipid Res 2005; 46:2699-2705. (Pubitemid 43107482)
60. Marques-Vidal P, Jauhiainen M, Metso J et al. Transformation of high density lipoprotein 2 particles by hepatic lipaseandphospholipidtransferprotein. Atherosclerosis 1997; 133:87-95. (Pubitemid 27322121)
61. Ross R. The pathogenesis of atherosclerosis: aperspective forthe 1990s. Nature 1993; 362:801-809. (Pubitemid 23132154)
62. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88:1785-1792.
63. Yla-Herttuala S, Palinski W, Rosenfeld ME et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84:1086-1095. (Pubitemid 19247577)
64. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15:551-561.
65. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9:471-474. (Pubitemid 28495557)
66. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116:1832-1844. (Pubitemid 350287108)
67. Nievelstein PF, Fogelman AM, Mottino G et al. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. A deep-etch and immunolocalization study of ultrarapidly frozentissue. ArteriosclerThromb 1991; 11:1795-1805.
68. Smith EB. Intimal and medial lipids in human aortas. Lancet 1960; 1:799-803.
69. Newman HA, Mc CE, Zilversmit DB. The synthesis of C14-lipids in rabbit atheromatous lesions. J Biol Chem 1961; 236:1264-1268.
70. Phillips GB, Dodge JT. Composition of phospholipids and of phospholipid fatty acids of human plasma. J Lipid Res 1967; 8:676-681.
71. Portman OW, Illingworth DR. Arterial metabolism in primates. Primates Med 1976; 9:145-223.
72. Hakomori S. Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. Annu Rev Biochem 1981; 50:733-764.
73. Kummerow FA, Cook LS, Wasowicz E et al. Changes in the phospholipid composition ofthe arterial cell can result in severe atherosclerotic lesions. J Nutr Biochem 2001; 12:602-607. (Pubitemid 32930056)
74. Hoff HF, Morton RE. Lipoproteins containing apo B extracted from human aortas. Structure and function. Ann N Y Acad Sci 1985; 454:183-194. (Pubitemid 16198850)
75. Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996; 16:4-11. (Pubitemid 26026925)
76. Schissel SL, Tweedie-Hardman J, Rapp JH et al. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996;98:1455-1464. (Pubitemid 26322072)
77. Schissel SL, Jiang X, Tweedie-Hardman J et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem 1998; 273:2738-2746. (Pubitemid 28133919)
78. Zilversmit DB, Mc CE, Jordan PH et al. The synthesis of phospholipids in human atheromatous lesions. Circulation 1961; 23:370-375.
79. Eisenberg S, Stein Y, Stein O. Phospholipases in arterial tissue. IV. The role of phosphatide acyl hydrolase. lysophosphatide acyl hydrolase, and sphingomyelin choline phosphohydrolase in the regulation of phospholipid composition in the normal human aorta with age. J Clin Invest 1969; 48:2320-2329.
80. Okwu AK,XuXX, Shiratori Yet al. Regulation ofthe threshold for lipoprotein-inducedacyl-CoA:cholesterol O-acyltransferase stimulation in macrophages by cellular sphingomyelin content. J Lipid Res 1994; 35:644-655. (Pubitemid 24113106)
81. Noel C, Marcel YL, Davignon J. Plasma phospholipids in the different types ofprimary hyperlipoproteinemia. J Lab Clin Med 1972; 79:611-621.
82. Rodriguez JL, Ghiselli GC, Torreggiani D et al. Very low density lipoproteins in normal and cholesterol-fed rabbits: lipid and protein composition and metabolism. Part 1. Chemical composition of very low density lipoproteins in rabbits. Atherosclerosis 1976; 23:73-83.
83. Zhang SH, Reddick RL, Piedrahita JA et al. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258:468-471.
84. Plump AS, Smith JD, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71:343-353.
85. Schlitt A, Blankenberg S, Yan D et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) 2006; 3:5.
86. Li Z, Basterr MJ, Hailemariam TK et al. The effect of dietary sphingolipids on plasma sphingomyelin metabolism and atherosclerosis. Biochim Biophys Acta 2005; 1735:130-134. (Pubitemid 40961968)
87. Devlin CM, Leventhal AR, Kuriakose G et al. Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol 2008; 28:1723-1730.
88. Leventhal AR, Chen W, Tall AR et al. Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J Biol Chem 2001; 276:44976-44983.
89. Schuchman EH, Desnick RJ. The Metabolic and Molecular Basis of Inherited Disease (Scriver CR, Beaudet AL, Sly WS and Valle D eds), McGraw-Hill, New York 1995; 2601-2624.
90. Slotte JP. Sphingomyelin-cholesterol interactions in biological and model membranes. Chem Phys Lipids 1999; 102:13-27. (Pubitemid 29438655)
91. Ridgway ND. Interactions betweenmetabolism and intracellular distribution ofcholesterol and sphingomyelin. Biochim Biophys Acta 2000; 1484:129-141. (Pubitemid 30175963)
92. Viana MB, Giugliani R, Leite VH et al. Very low levels of high density lipoprotein cholesterol in four sibs of a family with nonneuropathic Niemann-Pick disease and seablue histiocytosis. J Med Genet 1990; 27:499-504.
93. Tall AR, Wang N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest 2000; 106:1205-1207.
94. Jessup W, Gelissen IC, Gaus K et al. Roles of ATP binding cassette transporters Al and Gl, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol 2006; 17:247-257. (Pubitemid 43786058)
95. Gaus K, Kritharides L, Schmitz G et al. Apolipoprotein A-l interaction with plasma membrane lipid rafts controls cholesterol export from macrophages. FASEB J 2004; 18:574-576.
96. Mendez AJ, Lin G, Wade DP et al. Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the ABCAl-mediated lipid secretory pathway. J Biol Chem 2001; 276:3158-3166.
97. Landry YD, Denis M, Nandi S et al. ATP-binding cassette transporter Al expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem 2006; 281:36091-36101. (Pubitemid 46041342)
98. Gelissen IC, Harris M, Rye KA et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006; 26:534-540.
99. Wang N, Ranalletta M, Matsuura F et al. LXRinduced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterolmass effluxto HDL. Arterioscler Thromb Vasc Biol2006; 26:1310-1316. (Pubitemid 44305375)
100. Huang ZH, Gu D, Lange Y et al. Expression of scavenger receptor BI facilitates sterol movement between the plasma membrane and the endoplasmic reticulum in macrophages. Biochemistry 2003; 42:3949-3955. (Pubitemid 36402688)
101. Zhang W, Yancey PG, Su YR et al. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein Edeficient mice. Circulation 2003; 108:2258-2263. (Pubitemid 37363044)
102. Timmins JM, Lee JY, Boudyguina E et al. Targeted inactivation of hepatic Abcal causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005; 115:1333-1342. (Pubitemid 40629053)
103. Lee JY, Parks JS. ATP-binding cassette transporter Al and its role in HDL formation. Curr Opin Lipidol 2005; 16:19-25. (Pubitemid 40333362)
104. Landschulz KT, Pathak RK, Rigotti A et al. Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 1996; 98:984-995. (Pubitemid 26293317)
105. Stangl H, Hyatt M, Hobbs HH. Transport of lipids from high and low density lipoproteins via scavenger receptor-BI. J Biol Chem 1999; 274:32692-32698. (Pubitemid 129535297)
106. Kennedy MA, Barrera GC, Nakamura K et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005; 1:121-131. (Pubitemid 43977167)
107. Christiansen K, Carlsen J. Microvillus membrane vesicles from pig small intestine. Purity and lipid composition. Biochim Biophys Acta 1981; 647:188-195.
108. Danielsen EM, Hansen GH. Lipid raft organization and function in the small intestinal brush border. J Physiol Biochem 2008; 64:377-382.
109. Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transportto the apical cell surface. Cell 1992; 68:533-544.
110. Field FJ, Born E, Murthy S et al. Caveolin is present in intestinal cells: role in cholesterol trafficking?. J Lipid Res 1998; 39:1938-1950 (Pubitemid 28462351)
111. Garmy N, Taieb N, YahiN et al. Interaction of cholesterol with sphingosine: physicochemical characterization and impact on intestinal absorption. J Lipid Res 2005; 46:36-45. (Pubitemid 40066669)
112. Graf GA, Connell PM, van der Westhuyzen DR et al. The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae. J Biol Chem 1999; 274:12043-12048.
113. Babitt J, Trigatti B, Rigotti A et al. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 1997; 272:13242-13249. (Pubitemid 27216752)
114. Drobnik W, Borsukova H, Bottcher A et al. Apo AI/ABCAl-dependent and HDL3-mediated lipid efflux from compositionally distinct cholesterol-based microdomains. Traffic 2002; 3:268-278. (Pubitemid 34303259)
115. Nagao K, Takahashi K, Hanada K et al. Enhanced apoA-I-dependent cholesterol efflux by ABCA1 from sphingomyelin-deficient Chinese hamster ovary cells. J Biol Chem 2007; 282:14868-14874. (Pubitemid 47093358)
116. Zweerink MM, Edison AM, Wells GB et al. Characterization of a novel, potent and specific inhibitor of serine palmitoyltransferase. J Biol Chem 1992; 267:25032-25038.
117. Mandala SM, Frommer BR, Thornton RA et al. Inhibition of serine palmitoyl-transferase activity by lipoxamycin. J Antibiot (Tokyo) 1994; 47:376-379. (Pubitemid 24106530)
118. Miyake Y, Kozutsumi Y, Nakamura S et al. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun 1995; 211:396-403.
119. Kobayashi SFT, Hayashi T, NishijimaM et al. Catalytic asymmetric syntheses ofantifungal sphingofungins and their biological activity as potent inhibitors of serine palmitoyltransferase (SPT). J Am Chem Soc 1998; 120:908-919.
120. Chen JK, Lane WS, Schreiber SL. The identification of myriocin-binding proteins. Chem Biol 1999; 6:221-235. (Pubitemid 29368410)
121. Park TS, Rosebury W, Kindt EK et al. Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice. Pharmacol Res 2008; 58:45-51.
122. Li ZPT, Li Y, Pan X et al. Serine Palmitoyltransferase (SPT) Deficient Mice Absorb Less Cholesterol Biochim Biophys Acta in press. 2009.
123. Hojjati MR, Li Z, Jiang XC. Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice. Biochim Biophys Acta 2005; 1737:44-51. (Pubitemid 41550382)
124. Memon RA, Holleran WM, Moser AH et al. Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin. Arterioscler Thromb Vasc Biol 1998; 18:1257-1265. (Pubitemid 28376182)
125. MemonRA, HolleranWM, Uchida Y et al. Regulation of sphingolipid and glycosphingolipid metabolism in extrahepatic tissues by endotoxin. J Lipid Res 2001; 42:452-459. (Pubitemid 32270070)
126. Farrell AM, Uchida Y, Nagiec MM et al. UVB irradiation up-regulates serine palmitoyltransferase in cultured human keratinocytes. J Lipid Res 1998; 39:2031-2038. (Pubitemid 28462360)
127. Shimabukuro M, Higa M, Zhou YT et al. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem 1998; 273:32487-32490. (Pubitemid 28557623)
128. Dickson RC, Lester RL, Nagiec MM. Serine palmitoyltransferase. Methods Enzymol 2000; 311:3-9. (Pubitemid 29512744)
129. Longo CA, Tyler D, Mallampalli RK. Sphingomyelin metabolism is developmentally regulated in rat lung. Am J Respir Cell Mol Biol 1997; 16:605-612. (Pubitemid 127498293)
130. Geelen MJ, Beynen AC. Consumption of olive oil has opposite effects on plasma total cholesterol and sphingomyelin concentrations in rats. Br J Nutr 2000; 83:541-547 (Pubitemid 30319071)
131. Rotta LN, Da Silva CG, Perry ML et al. Undernutrition decreases serine palmitoyltransferase activity in developing rat hypothalamus. Ann Nutr Metab 1999; 43:152-158. (Pubitemid 29494860)
132. Merrill Jr. A.H. Characterization of serine palmitoyltransferase activity in Chinese hamster overy cells. Biochim Biophys Acta 1983; 754:284-291.
133. Hanada K, Hara T, Nishijima M. Purification of the serine palmitoyltransferase complex responsible for sphingoid base synthesis by using affinity peptide chromatography techniques. J Biol Chem 2000; 275:8409-8415. (Pubitemid 30180184)
134. Liu J, Zhang H, Li Z et al. Sphingomyelin Synthase 2 Is One of the Determinants for Plasma and Liver Sphingomyelin Levels in Mice. Arterioscler Thromb Vasc Biol. 2009.
135. Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol 2002; 22:1370-1380.
136. Separovic D, Hanada K, Maitah MY et al. Sphingomyelin synthase 1 suppresses ceramide production and apoptosis postphotodamage. Biochem Biophys Res Commun 2007; 358:196-202. (Pubitemid 46719102)
137. DingT, LiZ, Hailemariam T et al. SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglycerol metabolism and cell apoptosis. J Lipid Res 2008; 49:376-385. (Pubitemid 351213622)
138. Ko YG, Lee JS, Kang YS et al. TNF-alphamediated apoptosis is initiated in caveolae-like domains. J Immunol 1999; 162:7217-7223.
139. Triantafilou M, Miyake K, Golenbock DT et al. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 2002; 115:2603-2611. (Pubitemid 34778077)
140. Cerbon J, del Carmen Lopez-Sanchez R. Diacylglycerol generated during sphingomyelin synthesis is involved in protein kinase C activation and cell proliferation in Madin-Darby canine kidney cells. Biochem J 2003; 373:917-924. (Pubitemid 36981102)
141. Wakelam MJ. Diacylglycerol-when is it an intracellular messenger?. Biochim Biophys Acta 1998; 1436:117-126.
142. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7:281-294. (Pubitemid 46480971)
143. Mayor S, Maxfield FR. Insolubility and redistribution of GPIanchored proteins at the cell surface after detergent treatment. Mol Biol Cell 1995; 6:929-944.
144. Murriel CL, Mochly-Rosen D. Opposing roles of delta and epsilonPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery. Arch Biochem Biophys 2003; 420:246-254. (Pubitemid 37491108)
145. Hannun YA, Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol 2000; 10:73-80. (Pubitemid 30084778)
146. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 2002; 110:3-8. (Pubitemid 34743457)
147. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874. (Pubitemid 36019640)
148. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470:M55-62. (Pubitemid 30155606)
149. BranenL, HovgaardL, NitulescuM et al. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004; 24:2137-2142. (Pubitemid 39482442)
150. Whitman SC, Ravisankar P, Daugherty A. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J Interferon Cytokine Res 2002; 22:661-670. (Pubitemid 35034524)
151. Legler DF, Micheau O, Doucey MA et al. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalphamediated NF-kappaB activation. Immunity 2003; 18:655-664. (Pubitemid 36588582)
152. Hunter I, Nixon GF. Spatial compartmentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways inhuman airway smoothmuscle cells. Lipidrafts are essential for TNF-alpha-mediated activation of RhoA but dispensable for the activation of the NF-kappaB and MAPK pathways. J Biol Chem 2006; 281:34705-34715. (Pubitemid 46036676)
153. Higuchi M, Singh S, Jaffrezou JP et al. Acidic sphingomyelinase-generated ceramide is needed but not sufficient for TNFinduced apoptosis and nuclear factor-kappaB activation. JImmunol 1996; 157:297-304. (Pubitemid 26190561)
154. Gamard CJ, Dbaibo GS, Liu B et al. Selective involvement of ceramide in cytokine-induced apoptosis. Ceramide inhibits phorbol ester activation of nuclear factor kappaB. J Biol Chem 1997;272:16474-16481. (Pubitemid 27276474)
155. Luberto C, Yoo DS, Suidan HS et al. Differential effects of sphingomyelin hydrolysis and resynthesis on the activation of NF-kappa B in normal and SV40-transformed human fibroblasts. J Biol Chem 2000; 275:14760-14766. (Pubitemid 30339770)
156. Hailemariam TK, Huan C, Liu J et al. Sphingomyelin synthase 2 deficiency
157. Stone PH, Muller JE, Hartwell T et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution ofboth coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989; 14:49-57. (Pubitemid 19165535)
158. Grynberg A, Demaison L. Fatty acid oxidation in the heart. J Cardiovasc Pharmacol 1996; 28 Suppl 1:S11-17. (Pubitemid 26314973)
159. Calvani M, RedaE, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol 2000; 95:75-83. (Pubitemid 30251262)
160. Augustus AS, Kako Y, Yagyu H et al. Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake ofTG-derived FA. Am J Physiol Endocrinol Metab 2003; 284:E331-339. (Pubitemid 36120106)
161. Jacob S. Lipiddropletaccumulationintheheartduringfasting. ActaHistochem 1987; 82:149-152.
162. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997; 34:25-33. (Pubitemid 27261909)
163. Young ME, Guthrie PH, Razeghi P et al. Impaired long-chain fatty acid oxidation and contractile dysfunction inthe obeseZuckerratheart. Diabetes 2002; 51:2587-2595. (Pubitemid 34827411)
164. Finds BN, HanX, Courtois M et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulationby dietary fat content. Proc Natl AcadSciUSA2003; 100:1226-1231. (Pubitemid 36183984)
165. Yokoyama M, Yagyu H, Hu Y et al. Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem 2004; 279:4204-4211. (Pubitemid 38199007)